

The document was published with an inadvertent typographical error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug Evaluation and Research (HFD-313), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2073.

In FR Doc. 94-7246, appearing on page 14627, in the *Federal Register* of Tuesday, March 29, 1994, the following correction is made:

On page 14627, in the third column, in the title of the document, the word "PHOTOLEX" is corrected to read "PHOTOPLEX".

Dated: April 8, 1994.

David B. Barr,
Deputy Director, Office of Compliance, Center
for Drug Evaluation Research.
[FR Doc. 94-9043 Filed 4-13-94; 8:45 am]
BILLING CODE 4160-01-F

[Docket No. 92E-0133]

Determination of Regulatory Review Period for Purposes of Patent Extension; Supprelin®; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the *Federal Register* of June 2, 1992 (57 FR 23237), that announced its determination of the regulatory review period for purposes of patent extension for Supprelin® (histrelin acetate). The document was published with some mathematical errors. The document incorrectly stated, "FDA has determined that the applicable regulatory review period for Supprelin® is 2,876 days. Of this time, 1,930 days occurred during the testing phase of the regulatory review period, while 946 days occurred during the approval phase." It should have stated, "FDA has determined that the applicable regulatory review period for Supprelin® is 2,878 days. Of this time, 1,931 days occurred during the testing phase of the regulatory review period, while 947 days occurred during the approval phase." This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-1382.

In FR Doc. 92-12846, appearing on page 23237 in the *Federal Register* of June 2, 1992, the following corrections

are made: On the same page, in the second column, in the second line from the bottom, "2,876" is corrected to read "2,878"; and in the last line, "1,930" is corrected to read "1,931"; and in the third column, in line 2, "946" is corrected to read "947".

Dated: April 6, 1994.

Stuart L. Nightingale,
Associate Commissioner for Health Affairs.
[FR Doc. 94-9047 Filed 4-13-94; 8:45 am]
BILLING CODE 4160-01-F

Health Resources and Services Administration

The Ryan White Comprehensive AIDS Resources Emergency Act of 1990—Early Intervention Services

AGENCY: Health Resources and Services Administration, PHS.

ACTION: Notice of pre-application technical assistance workshops.

SUMMARY: The Health Resources and Services Administration will hold pre-application technical assistance workshops for competing applicants under Title III(b), HIV Early Intervention Services, of the Ryan White Comprehensive AIDS Resources Emergency Act of 1990, Public Law 101-381.

Eligible applicants are Migrant and Community Health Centers under sections 329 and 330 of the Public Health Service (PHS) Act; Health Care for the Homeless Program grantees under section 340 of the PHS Act; Comprehensive Hemophilia Diagnostic and Treatment Centers; family planning grantees under section 1001 of the PHS Act (other than States); Federally Qualified Health Centers under section 1905(l)(2)(B) of the Social Security Act and other public and private nonprofit entities that provide comprehensive primary care services to populations at risk of HIV disease.

PURPOSE: The purpose of each technical assistance workshop is to disseminate relevant program information and review HIV Early Intervention Services program expectations. Eligible entities will have an opportunity to review the program guidance and to receive technical assistance pertaining to all aspects of writing and implementing grant applications under Title III(b), HIV Early Intervention Services.

CONTACT: Anyone interested in attending the meeting should contact Ms. Eugenia F. Adams, Division of Programs for Special Populations, Bureau of Primary Health Care, room 9-8D3, 4350 East-West Highway,

Bethesda, Maryland 20814. Telephone: (301) 594-4443. Costs of attending are to be borne by prospective applicants.

Date and Time: April 20, 1994, 10 a.m. to 5 p.m.

Place: PHS Regional Office II, room 305C, 26 Federal Plaza, New York, NY. Enter building on Duane St.

Date and Time: April 25, 1994, 9 a.m. to 5 p.m.

Place: Los Angeles Airport Hilton Towers Hotel, 5711 West Century Blvd., Los Angeles, CA.

Date and Time: April 25, 1994, 10 a.m.—5 p.m.

Place: PHS Regional Office V, room 328, 77 W Jackson Blvd., West Jackson Blvd. and Clark St., Metcalf Building, Chicago, IL.

Date and Time: April 28, 1994, 9 a.m.—5 p.m.

Place: PHS Regional Office VI, room 1230, 1200 Main Tower, Dallas, TX.

Dated: April 8, 1994.

Ciro Sumaya,
Administrator.

[FR Doc. 94-8996 Filed 4-13-94; 8:45 am]
BILLING CODE 4160-15-P

National Institutes of Health

National Cancer Institute; Notice of Meeting (Board of Scientific Counselors, Division of Cancer Treatment)

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Board of Scientific Counselors, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, April 26, 1994, Building 31C, Conference Room 6, 9000 Rockville Pike, Bethesda, Maryland 20892.

This meeting will be open to the public on April 26 from 1 p.m. to approximately 5 p.m., to discuss the recent events surrounding the data falsification in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study in Montreal, Canada. Attendance by the public will be limited to space available.

Ms. Carole Frank, Committee Management Officer, National Cancer Institute, Executive Plaza North Building, room 630E, National Institutes of Health, Bethesda, Maryland 20892 (301-496-5708) will provide summaries of the meeting and rosters of committee members upon request.

Dr. Bruce A. Chabner, Director, Division of Cancer Treatment, National Cancer Institute, Building 31, room 3A44, National Institutes of Health, Bethesda, Maryland 20892 (301-496-4291) will furnish substantive program information.

Individuals who plan to attend and need special assistance, such as sign